N‐Terminal Pro‐B‐Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID‐19 in a Nationwide Hospitalized Cohort
O’Donnell C, Ashland M, Vasti E, Lu Y, Chang A, Wang P, Daniels L, de Lemos J, Morrow D, Rodriguez F, O’Brien C. N‐Terminal Pro‐B‐Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID‐19 in a Nationwide Hospitalized Cohort. Journal Of The American Heart Association 2021, 10: e022913. PMID: 34889112, PMCID: PMC9075235, DOI: 10.1161/jaha.121.022913.Peer-Reviewed Original ResearchConceptsElevated NT-proBNPCardiovascular risk factorsNT-proBNPHospital mortalityHeart failureRisk factorsCOVID-19N-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideElevated NT-proBNP concentrationsElevated NT-proBNP levelsIntensive care unit admissionLog-transformed NT-proBNPMajor adverse cardiac eventsMore cardiovascular risk factorsPrior heart failureAdverse cardiac eventsCare unit admissionNT-proBNP levelsNT-proBNP concentrationsObservational cohort studyShorter median timeRisk of deathUnit admissionCardiac events